Clinical Trial Update: A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 1/2 clinical trial evaluating ARV-471 alone and in combination with palbociclib (Ibrance) in patients with estroge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARV-471
• Ibrance (palbociclib) (palbociclib)

Snippet

Sponsor: Arvinas Estrogen Receptor, Inc. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED